Company signals · Biotech & Pharma
Genentech
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: Against a Talent Market Index of 112.9 (Hot) (up 11.4 month-on-month), Americas is at rising (+2.5pts) on signal share.
Genentech: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 23 tracked companies.
Signals at Genentech
More signals across Biotech & Pharma
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Partnership · Americas
Basecamp Research →Basecamp Research integrated its EDEN antibiotic and vaccine design models into Claude Science, enabling scientists to design antibiotics and prioritize vaccine targets through Claude's interface.
Ma Activity · Americas
Biogen →Biogen acquired Apellis Pharmaceuticals for $5.6B and subsequently paused or canceled the majority of research programs that came with the acquisition, laying off a small number of employees from Apellis.
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Intelligence powered by Autonodal ↗